MA-BRIGHTCOVE/WIBBITZ
13.7.2021 15:02:14 CEST | Business Wire | Press release
Media professionals, marketers, and corporate communicators can now rapidly expand their catalogs of business video with a new, tightly knit integration of the Wibbitz video creation tool and Brightcove ® (NASDAQ: BCOV), the global leader in video for business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005375/en/
With smart automation driving Wibbitz video creation, the combination of Brightcove and Wibbitz is one of the easiest and most effective ways for companies to quickly create professional quality short-form videos that engage viewers, nurture sales leads through to closure, and provide valuable information to shareholders, customers, and employees.
Creators, even those with no experience, can now access Wibbitz from their Brightcove Video Cloud interface and intuitively create polished videos from scratch. Wibbitz provides templates and rights-cleared photos and music tracks, animations, transitions, video clips, and other media. Users can then distribute the newly created videos through the Brightcove platform to any person on any device and on any channel, anywhere in the world. The integration also makes it easy to use Wibbitz to refresh videos stored in a Brightcove library with new content or effects before redistribution.
“As a long-time Wibbitz user, I’m excited about the integration with Brightcove and the ability to easily bring more scale, security, and reliability to our video content,” said Marco Viganò, Chief Technology Officer, Condé Nast Italy. “We believe video is the most powerful communications tool to engage our audiences. To us, the Wibbitz and Brightcove combination is now a single, seamless experience of video creation, distribution, and optimization.”
“Creators use Wibbitz to tell their stories with video, and they need the most reliable, comprehensive, and effective solution to make sure those stories reach their audience. Brightcove hits the mark,” said Zohar Dayan, Chief Executive Officer, Wibbitz. “This partnership simplifies video workflows to make each step easier, from production to publishing and analytics, so media companies and enterprises can focus on sharing stories that drive real impact.”
“Although Brightcove can easily manage, play, and measure any video created in any tool, we want to help make creators’ lives easier,” said Namita Dhallan, Chief Product Officer, Brightcove. “That means lowering the barrier to creation, especially for organizations that want to quickly and easily build up video volume and execute new video strategies themselves. Wibbitz is a great way to do that.”
Wibbitz and Brightcove exchange all relevant data, including authentication via single sign-on, user profile information, and available video files. Wibbitz also helps organizations ensure that every video is on brand with the right logos, watermarks, custom fonts, and color palettes.
To try Wibbitz for free, visit here .
About Wibbitz
Wibbitz is a video creation company that empowers content teams to produce professional short-form video. The Wibbitz online platform makes it quick and easy to create video for social media, news & entertainment coverage, marketing, communications, recruitment, events, and more. Creators have access to customizable video templates, drag-and-drop editing tools, a team of in-house experts, and millions of licensed photos, videos, and soundtracks. Wibbitz powers video for leading brands including HubSpot, Bloomberg, Condé Nast, S&P Global, Bain & Company, BP, and more. Wibbitz was founded in 2011 and has offices in New York City, Tel Aviv, and Paris. For more information, visit www.wibbitz.com and follow @wibbitz .
About Brightcove Inc.
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom